PMLiVE5d
GSK’s investigational antibiotic granted FDA priority review for urinary tract infections
GSK’s new drug application for its investigational oral antibiotic gepotidacin has been accepted for priority review by the ...
PMLiVE5d
Precision, planning and creativity for launch excellence in a volatile sector
Few organisations will get it that wrong, but the pharmaceutical launch pad is scorched with failure and the debris from ...
PMLiVE5d
Stirred becomes first UK health comms agency to achieve EcoVadis Platinum Medal
Stirred has announced that it has been awarded a Platinum Medal from EcoVadis, placing it in the top 1% of companies globally ...
PMLiVE6d
Amgen shares positive late-stage results for Uplizna in generalised myasthenia gravis
Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon ...
PMLiVE7d
J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis
Johnson & Johnson’s (J&J) investigational FcRn blocker nipocalimab has demonstrated sustained disease control in adolescents with the rare autoimmune disease generalised myasthenia gravis (gMG), ...
PMLiVE6d
Sex, Gender, and the Brain: The Women’s Brain Foundation and Medscape Education Announce Groundbreaking Learning Centre
LONDON–(BUSINESS WIRE)–The Women’s Brain Foundation (WBF), the global pioneer that has advanced the inclusion of sex- and gender-based evidence-generation in all research, drug development, and ...
PMLiVE13d
Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval
Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...
PMLiVE15d
Merck’s Keytruda shows promise as perioperative head and neck cancer treatment
Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...
PMLiVE13d
Roche’s Itovebi combination granted FDA approval for advanced breast cancer
Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...
PMLiVE20d
Bristol Myers Squibb’s Opdivo regimen granted FDA approval in NSCLC
Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a perioperative treatment regimen for adults with non-small cell lung cancer (NSCLC) ...
PMLiVE9d
FDA advisory committee recommends Stealth’s elamipretide for Barth syndrome
A US Food and Drug Administration (FDA) panel of experts has voted in support of Stealth BioTherapeutics’ elamipretide for Barth syndrome, an ultra-rare genetic disease that affects approximately 150 ...